Aditxt, Inc.ADTXNASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics Earnings Growth Financials Insiders

Latest News

businesswire.com

Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced the acquisition of Ignite Proteomics, LLC (“Ignite”), a commercial-stage precision oncology company focused on addressing a critical challenge in cancer care: optimizing therapy selection. Ignite's functional proteomics platform has demonstrated the ability to identify cancer therapy responses that may not be cap.

businesswire.com

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-8 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on March 9, 2026, the Company's common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company's stockholders at the r.

defenseworld.net

Comparing Aditxt (NASDAQ:ADTX) & Ernexa Therapeutics (NASDAQ:ERNA)

Ernexa Therapeutics (NASDAQ: ERNA - Get Free Report) and Aditxt (NASDAQ: ADTX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability. Insider and Institutional Ownership 70.6% of Ernexa Therapeutics

defenseworld.net

Aditxt, Inc. (NASDAQ:ADTX) Short Interest Down 18.8% in February

Aditxt, Inc. (NASDAQ: ADTX - Get Free Report) saw a significant decline in short interest in February. As of February 13th, there was short interest totaling 40,608 shares, a decline of 18.8% from the January 29th total of 49,980 shares. Based on an average daily trading volume, of 186,308 shares, the short-interest ratio is currently 0.2

defenseworld.net

Aditxt, Inc. (NASDAQ:ADTX) Sees Significant Decrease in Short Interest

Aditxt, Inc. (NASDAQ: ADTX - Get Free Report) saw a large decrease in short interest in January. As of January 30th, there was short interest totaling 49,980 shares, a decrease of 53.4% from the January 15th total of 107,279 shares. Currently, 6.8% of the company's stock are sold short. Based on an average trading volume of

defenseworld.net

Reviewing Avalo Therapeutics (NASDAQ:AVTX) and Aditxt (NASDAQ:ADTX)

Aditxt (NASDAQ: ADTX - Get Free Report) and Avalo Therapeutics (NASDAQ: AVTX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability. Profitability This table compares Aditxt and Avalo Therapeutics'

defenseworld.net

Short Interest in Aditxt, Inc. (NASDAQ:ADTX) Declines By 31.2%

Aditxt, Inc. (NASDAQ: ADTX - Get Free Report) was the target of a large decline in short interest in the month of December. As of December 15th, there was short interest totaling 86,655 shares, a decline of 31.2% from the November 30th total of 125,952 shares. Approximately 11.9% of the company's shares are short sold. Based

feeds.benzinga.com

Stock Market Today: S&P 500, Dow Futures Gain As Jobs Data Weighs On Outlook—Lennar, Micron Technology, Children's Place In Focus

U.S. stock futures rose on Wednesday after Tuesday's mixed close. Futures of major benchmark indices advanced.

feeds.benzinga.com

What Sparked Aditxt (ADTX) Stock's 52% After‑Hours Surge?

Aditxt shares surged 52% after hours following the company's filing of a definitive proxy statement for a special stockholder meeting in January 2026.

defenseworld.net

Critical Analysis: Addex Therapeutics (NASDAQ:ADXN) & Aditxt (NASDAQ:ADTX)

Aditxt (NASDAQ: ADTX - Get Free Report) and Addex Therapeutics (NASDAQ: ADXN - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability. Valuation and Earnings This table compares Aditxt and

businesswire.com

Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta's Planned IPO, And Evofem's Plan to Regain a National Listing

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today shared its growth vision under the bitXbio™ strategy. bitXbio™ (pronounced “bit-by-bio”) is a transformational framework designed to connect public markets, blockchain and Web3, and digital asset treasuries for advancing breakthrough health innovations. The bitXbio™ strategy is intended to scale Aditxt as a social innovati.

defenseworld.net

Aditxt, Inc. (NASDAQ:ADTX) Sees Large Growth in Short Interest

Aditxt, Inc. (NASDAQ: ADTX - Get Free Report) was the recipient of a significant growth in short interest during the month of October. As of October 15th, there was short interest totaling 760,300 shares, a growth of 119.4% from the September 30th total of 346,600 shares. Based on an average trading volume of 2,260,000 shares, the

businesswire.com

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-113 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on November 3, 2025, the Company's common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company's stockholders at.

businesswire.com

Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), has begun enrollment in their prospective clinical study evaluating the Mitomic® Endometriosis Test (MET™), a novel blood-based diagnostic designed to aid in the early detection of endometriosis. The study, “Mitochondrial DNA Deletions in Plasma as a Diagnostic.

prnewswire.com

Evofem Announces Voting Results from Special Meeting of Stockholders

-- Evofem Shareholders Did Not Approve the Merger with Aditxt -- -- Evofem Pivots to Target National Listing for Stock, Growth Capital to Catalyze Net Sales -- SAN DIEGO , Oct. 20, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCID: EVFM) ("Evofem" or the "Company"), today announced that at a Special Meeting of Stockholders held this morning, its stockholders did not approve the proposal to adopt the Amended and Restated Merger Agreement dated July 12, 2024, as subsequently amended (the "Merger Agreement"), between the Company, Aditxt, Inc. (NASDAQ: ADTX), and Adifem, Inc., a wholly owned subsidiary of Aditxt, under which Aditxt intended to acquire Evofem. As a result, Evofem has exercised its rights to terminate the Merger Agreement.

prnewswire.com

Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms

-- 130% increase in traffic to PHEXXI.com, the website for Evofem's hormone-free prescription contraceptive PHEXXI® (lactic acid citric acid and potassium bitartrate) -- -- PHEXXI® is #1 most followed contraceptive brand on social media by healthcare providers -- SAN DIEGO , Sept. 11, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (Evofem) (OTCID: EVFM) today announced the conclusion and exciting impact of its groundbreaking August 2025 "Say Vagina" campaign, which aimed to normalize the use of clinical anatomical language and to combat the widespread censorship of essential medical terminology.

prnewswire.com

Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting

-- Special Meeting to be held on September 26, 2025 -- SAN DIEGO , Sept. 9, 2025 /PRNewswire/ -- In an update to stockholders today, Evofem Biosciences, Inc. ("Evofem" or the "Company") (OTCID: EVFM) anticipates the approval of the transactions (the "Merger") contemplated by the Amended and Restated Merger Agreement dated as of July 12, 2024, as amended, (collectively, the "Merger Agreement"), with Aditxt, Inc. (Nasdaq: ADTX) and Adifem, Inc., a wholly-owned subsidiary of Aditxt, at the Company's Special Meeting of Stockholders (the "Special Meeting") to be held on September 26, 2025.

businesswire.com

Aditxt's Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt”, or the “Company”), a social innovation platform accelerating promising health innovations, today announced an update on its wholly owned subsidiary Adimune, Inc. (“Adimune”), which is pioneering a DNA-based therapeutic platform designed to reprogram the immune system. Adimune's intellectual property portfolio now includes 96 granted and 22 pending patents that are owned or exclusively licensed by Aditxt, supporting t.

prnewswire.com

Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law

-- Passage of House Bill 3489 allows Illinois pharmacists to prescribe non-hormonal and emergency contraceptives -- -- Ensures a broader range of contraceptive choices is available to women state-wide -- SAN DIEGO , Aug. 21, 2025 /PRNewswire/ -- On August 15, 2025, Illinois enacted House Bill 3489, a measure designed to broaden access to contraception for its residents. This legislation permits pharmacists to prescribe a wider array of contraceptive options, including PHEXXI® (lactic acid, citric acid, and potassium bitartrate) , the hormone-free on-demand contraceptive vaginal gel from Evofem Biosciences (OTCID: EVFM).

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance